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Abstract 
We describe a sensitive, robust, high-throughput method for quantifying the ability of 
metastatic tumour cells to colonise a secondary organ. Metastasis is the leading cause of death 
in cancer patients and successful colonisation of the secondary organ is the rate-limiting step 
in the metastatic process, thus experimental methods that can be used to interrogate the key 
factors required for this critical step are of great importance. The experimental metastasis 
assay involves tail vein injection of cancer cells into the mouse and determination of the 
resulting secondary organ colonisation, primarily in the lung. This assay can be used to 
investigate factors that regulate metastatic colonisation both at the tumour cell intrinsic level 
(via manipulation of the tumour cells prior to injection) and tumour cell extrinsic level (such as 
the tissue microenvironment, via the use of genetically modified mice or agents such as 
antibodies, drugs, etc). With this method we have robustly screened more than 950 genetically-
modified mouse lines to identify novel microenvironmental regulators of metastatic colonisation. 
Details are given on the appropriate cell numbers, handling of the cells, recipient animals, and 
injection techniques. Further, we discuss key experimental design considerations, including 
the choice of method used to determine metastatic burden and statistical analysis of the results, 
as well as providing trouble shooting tips and identification of the factors that contribute to 
experimental variability. 
 
 
Introduction 
Metastasis, a major contributor to cancer-related deaths, is a complex multi-step 
process, which involves the invasion of adjacent tissues, intravasation, transport through the 
circulatory system, arrest at a secondary site, extravasation and growth in a secondary organ 
(Figure 1). Tumour cells that have undergone intravasation are able to survive in the circulation 
with high efficiency and extravasate equally as efficiently, with >80% of cells successfully 
completing this process [reviewed in Chambers et al., 2000 1], Indeed, the ability to extravasate 
in vivo is not necessarily predictive of subsequent metastasis formation (with metastatic ras-
transformed and control fibroblasts extravasating equally well 2. Thus is it the post-
extravasation steps that are much less efficient and more variable with in vivo videomicroscopy 
studies demonstrating that only a small proportion of extravasated cells begin to grow (~2% of 
injected cells), and only a subset of micrometastases continue to form macrometastases 
(~0.02% of injected cells) 3. Therefore, the ability to grow and ‘conquer’ a foreign environment, 
i.e., to ‘colonise’ a secondary site, is the rate-limiting step in the metastatic cascade. 
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 The colonisation of a secondary organ is dependent upon both tumour cell intrinsic and 
extrinsic factors. The importance of tumour cell intrinsic factors is highlighted by exome 
sequencing of primary and matched metastatic tumour tissues from patients to identify the 
genetic divergence of metastases from the primary tumour 4, as well as the identification of 
metastasis-suppressor genes, such as NM23 and KISS1 [reviewed in Hurst & Welch, 2011 5]. 
The importance of extrinsic factors, i.e., the microenvironment (or ‘host’), which includes 
fibroblasts, immune cells, and endothelial cells, is highlighted by reports identifying 
constitutional genetic polymorphisms that substantially influence the metastatic efficiency of 
tumors (such as Sipa1 6) and a recent study in which we used an experimental metastasis 
assay to screen 810 mutant mouse lines and identified 23 genes as potential host regulators 
of metastatic colonisation 7. 
 
Tools for studying metastatic colonisation 
Much in vitro work has been performed to assess the metastatic propensity of tumour 
cells by examining their abilities in terms of adhesion and invasion. However, whilst these 
characteristics are necessary for metastasis, by themselves they are not sufficient as cells that 
lack the ability to complete other steps of the metastatic cascade, such as successful growth 
at the secondary site (‘colonisation’), may not form macroscopic metastatic lesions in vivo 8-10. 
In addition, in vitro assays do not take into account tumour cell extrinsic factors, such as the 
surrounding stroma, and the haematopoietic system. Thus the study of metastasis is ideally 
performed in vivo. The chorioallantoic membrane of the developing chick embryo is rich in 
blood vessels and tumour cell xenografts can be injected onto the membrane and their ability 
to intravasate and disseminate can be monitored 11. More recently, a high-throughput system 
for in vivo assessment of tumour cell intrinsic or microenvironmental modifiers of metastasis 
was described using zebrafish 12. However, the mouse remains the most widely used in vivo 
system for modeling metastasis, due to their physiological and genetic similarities to humans. 
Modelling metastasis in the mouse can be achieved through the use of autochthonously 
arising metastatic lesions or transplantation models (Figure 1) [reviewed in Khanna and Hunter, 
2005 13]. Autochthonous (‘endogenous’) tumours capable of completing the entire metastatic 
process can be generated by the use of genetically-modified (GM) mice (such as MMTV-PyMT 
mice which develop mammary tumours that metastasize to the lung) and/or chemically-treated 
mice (such as 7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoyl-phorbol-13-
acetate (TPA)-treated mice that form squamous cell carcinomas skin tumors that metastasize 
to the lymph nodes and lungs). However, it can take many months for the metastatic lesion to 
arise, and it can happen in a very asynchronous fashion (with great variability from mouse to 
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mouse), so is not amenable to high-throughput screening. In addition, it does not allow 
modification of tumour cell intrinsic factors to determine how they affect the ability of the tumour 
cell to metastasize. An alternative is the spontaneous metastasis assay, in which tumour cells 
are orthotopically transplanted into the mouse. However, it can take weeks for metastasis to 
occur, and unless subcutaneously/intradermally injecting cells, this technique comes with the 
added complication that it involves surgery (such as administration of tumour cells into the 
mammary fat pads or brain) or use of anaesthetics and an imaging apparatus (such as 
administration of cancer cells directly into the colon, kidney or lung). The alternative is the 
experimental metastasis assay, in which cells are injected directly into the circulation, can take 
as little as 7-10 days, does not require any imaging or surgical equipment or skills, and allows 
assessment of both tumour cell intrinsic and extrinsic factors of metastatic colonisation. 
 
Development and applications of the method 
The experimental metastasis assay determines the colonisation ability/potential of 
tumour cells by the measurement of the tumour burden in specific organs of the animal after 
injection of the tumour cells directly into the haematogenous circulation. It has been a long-
standing technique in the metastasis field, with studies in the early 1950’s demonstrating that 
the injection of rabbit V2 carcinoma cells into either the portal vein/hepatic artery or a systemic 
vein led to the development of tumors in the liver or lung, respectively 14. In support of the “seed 
and soil” concept that Stephen Paget hypothesized in 1889 to explain the non-random pattern 
of cancer metastasis 15, seminal work by Fidler and co-workers in the late 1970’s used the 
experimental metastasis assay to demonstrate that the organ selectivity of metastatic cells is 
dependent on both tumour cell properties and host factors 16,17. 
Here we have taken the fundamentals of the experimental metastasis assay, and 
generated a method that is robust enough to be performed as a bespoke or high-throughput 
assay, to identify both tumour intrinsic and extrinsic factors that regulate metastatic colonisation. 
Our protocol involves intravenous injection of tumour cells into the lateral tail vein of mice, 
followed by determination of metastatic burden of the secondary organ, primarily the lung, 10 
days later (Figure 2). It can be performed using either murine or human tumour cell lines, in 
both immunodeficient and/or immunocompetent mice. 
This method can be used to examine tumour cell intrinsic and extrinsic factors that can 
regulate metastatic colonisation. Tumour cell intrinsic factors can be examined via prior 
manipulation of the tumour cell line in vitro (such as by CRISPR/Cas9). This could be done 
using both a targeted approach, in which guide RNAs are used to target a single gene to 
determine the metastatic capabilities of that modified cell line, or as a screening approach, in 
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which a library of guide RNAs are used, to determine which gene(s) confers metastatic 
potential and enable successful colonisation of a secondary organ. This method can also be 
used to compare the metastatic potential of tumour cell lines that have undergone different 
selection processes in vitro or in vivo (Figure 3a). The cell lines can be either of murine origin, 
which allows injection into syngeneic wildtype or genetically modified mice and has the 
advantage of an immunocompetent host, or of human origin, if injected into immunodeficient 
mice (such as NOD-SCID mice), to avoid immunological rejection. 
The role of tumour cell extrinsic factors can be examined by the use of GM mice carrying 
specific genetic modifications, such as null alleles, point mutations, gain-of-function alleles or 
conditional alleles. Using this protocol we have screened 950 genetically-modified mouse lines 
to discover novel genes that contribute to microenvironmental regulation of metastatic 
colonisation (Figure 3b; the results of 810 mutant lines screened has been previously 
described 7). Examples of such genes include Slc9a3r2 (Slc9a3r2 mutant mice showed 
increased colonisation) and Arhgef1 (Arhgef1 mutant mice showed decreased colonisation; 
Figure 3c).  
The use of bone marrow chimaeras, where the host animal is irradiated to eliminate the 
stem cells in their bone marrow so they can be replaced with donor bone marrow, allows 
examination of the role of the haematopoietic (immune) system in metastatic colonisation. For 
example, the decreased metastatic colonisation phenotype observed in Arhgef1 mutant mice 
is mediated, at least in part, by the haematopoietic system, as bone marrow chimaeras given 
Arhgef1 mutant bone marrow also showed a decreased metastatic colonisation phenotype 
(Figure 3d). Similarly, when used in combination with in vivo depletion techniques, in which 
animals are depleted of specific components of the haematopoietic system via administration 
of antibodies, the role of individual haematopoietic cell types in metastatic colonisation can be 
interrogated. For example, administration of anti-asialo ganglio-N-tetraosylceramide (ASGM1) 
antiserum to deplete natural killer (NK) cells, results in increased metastatic colonisation, 
confirming the key role of NK cells in controlling metastasis (Figure 3e). Finally, this method 
can also be used in a pre-clinical setting, to assess the effectiveness of potential therapeutic 
drugs on metastatic colonisation [reviewed in Steeg, 2016 18]. 
 
Limitations of the method 
As the experimental metastasis assay involves injection of cancer cells directly into the 
bloodstream, it bypasses the early steps of the metastatic pathway, specifically the invasion of 
the cancer cells into the surrounding tissue and subsequent intravasation. However, it can be 
argued that these early steps are not the ‘critical’ ones as many tumour cells break away from 
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the primary tumour mass and can be found in the blood stream as ‘circulating tumour cells’ 
(CTCs). The ability to generate CTCs is however, not indicative of their metastatic potential as 
preclinical models have demonstrated that within 24 hours of intravenous administration, less 
than 0.1% of the tumour cells remain viable and that less than 0.01% of these surviving CTCs 
can produce metastases 19. 
After tail vein injection, the first capillary bed that the tumour cells encounter are those 
of the lung (if they pass through the lungs, they enter the arterial system and eventually pass 
into the portal circulation) and thus the experimental metastasis assay using the tail vein route 
tends to favour colonisation of the lung. However, it can be argued that metastases in the lung 
are found in many cancer types (breast cancer, colon cancer, bladder cancer and melanoma, 
to name a few 20), so it is a highly clinically relevant organ for investigation of colonisation 
factors. Furthermore, although not commonly used, there are some tumour cell lines that have 
been shown to colonise other organs after tail vein injection; EL-4 cells (a C57BL/6 
dimethylbenzanthracene-induced thymoma line 21), ESb cells (a DBA/2 methylcholanthrene-
induced lymphoma line) 22 and RAW117-H10 cells (a BALB/c large-cell lymphoma line 23 all 
colonise the liver after tail vein injection. In contrast, other cells line colonise multiple organs, 
such the C57BL/6J methylcholanthrene-induced pleomorphic myofibrosarcoma ER 15-P cell 
line, that colonises the lungs, mediastinal lymph nodes, liver, kidneys and brain (with repeated 
administration of tumor cells from liver metastases into the tail vein leading to selection of a 
tumor cell line with a tendency to liver metastasis) 24. Alternatively, injection of tumour cells into 
the portal vein or left cardiac ventricle leads to colonisation of the liver and bone/brain, 
respectively. 
 
Experimental design 
Mice should be matched by sex, age and genetic background as all of these factors can 
influence metastatic colonisation (Box 1 and Figure 4). The experimenter should ensure that 
the experiment is performed in accordance with local animal research regulations. The tumour 
cell line should be thawed and passaged as minimally as possible prior to injection, to ensure 
they maintain their potency in vivo. In this protocol we provide details for the B16-F10 mouse 
melanoma cell line that is widely used, however, many other tumour cell lines can be used. 
After administration of the tumour cells, the metastatic burden of any tissue can be determined 
in three ways, depending upon the cell line administered (Box 2 and Figure 5): specifically 
visually counting the number of lesions (if a pigmented cell line is used), counting of the number 
of lesions from H&E-stained sections of the tissue (applicable for all cell lines) or qPCR for the 
level of mCherry expression relative to vimentin expression (once the cell line has been 
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transfected with an mCherry-expressing plasmid; use of a fluorescent tag also means the 
metastatic lesions can be counted under a fluorescence microscope). Wherever possible, the 
individual performing the assessment of metastatic burden should be blinded to the identity of 
the samples (e.g., which samples came from the mutant/drug-treated mice versus the 
control/vehicle-treated mice, or which samples were from mice dosed with modified cells 
versus mice dosed with unmodified cells). 
 
Statistical analysis 
To avoid temporal effects confounding the statistical analysis, test and control samples 
should always be run concurrently. If a low sample size within a single experimental run, we 
recommend the use of the non-parametric Mann-Whitney to identify significant differences 
between the groups before assessing the biological significance using the ‘metastatic ratio’.  
We suggest both a statistical significance test and biological effect size cut off to select a 
treatment for further screening (for instance in our screen we used a Mann-Whitney P value of 
≤ 0.0175 with a metastatic ratio of ≤ 0.6 or ≥ 1.6 7). If significant in the initial cohort assayed, 
the experiment should be independently repeated an additional three times and the data from 
all cohorts processed through an integrative data analysis to determine those lines that were 
statistically significant. This two-step process ensures robust reproducible findings are 
identified. 
Integrative Data Analysis 25 assesses for treatment effect across multiple experiments 
by treating each experiment as a fixed effect. We recommend implementing an iterative top 
down modeling strategy, starting with the most comprehensive model (either Eq. [1], or [2]) 
appropriate for the collection strategy implemented and ensuring the model only includes terms 
where the terms can be independently assessed [full details including code is published 
elsewhere: van der Weyden et al., manuscript submitted].  
Y=β0 + β1Sex + β2Experiment + β3Treatment + β4Sex*Treatment       [Eq.1]     
Y=β0 + β2Experiment + β3Treatment      [Eq. 2] 
The optimisation process first selects a covariance structure for the residual, then the model 
reduced by removing non-significant fixed effects, and finally the treatment effect is tested and 
model diagnostics visualised. The issue of multiple testing can be managed by adjusting the 
calculated p values to either control the family wise error rate (FWER) or the more sensitive 
false discovery rate (FDR).  
 
 
MATERIALS 
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REAGENTS 
• Cells (typically established tumour cell lines, of human or mouse origin). ! CAUTION 
Ensure the cells have been tested and found to be free of mycoplasma and any mouse 
pathogens. 
• Cell culture medium (with serum and supplements) and reagents for growing, passaging 
and collecting the cells (depending on the specific requirements for those cells). 
• Recipient mice (age-, sex- and strain-matched adult mice, ideally 6-8 weeks of age). ! 
CAUTION All animal studies should be carried out according to all relevant 
governmental and institutional animal care and research legislation and regulations. 
• Wet-ice. 
• Phosphate buffered saline (without Ca2+ and Mg2+). 
• Optional (if performing analysis of metastatic burden by qPCR): reagents to extract 
genomic DNA from tissue homogenates (we use Qiagen Puregene Core A) qPCR kit 
for probe based assays (we use Qiagen QuantiNova probe PCR kit); qPCR 
consumables (96 or 384 well plate and seals); Vimentin (VIC conjugated primer 
limited) and mCherry (FAM conjugated) from Life Technologies (as shown below). 
Mouse vimentin (request primer limited format) - primer and probe sequences 
AGC TGC TAA CTA CCA GGA CAC TAT TG  
CGA AGG TGA CGA GCC ATC TC  
VIC - CCT TCA TGT TTT GGA TCT CAT CCT GCA GG – TAMRA 
 
mCherry- primer and probe sequences 
GAC CAC CTA CAA GGC CAA GAA G  
AGG TGA TGT CCA ACT TGA TGT TGA  
6FAM - CAG CTG CCC GGC GCC TAC A - TAMRA 
 
 
EQUIPMENT 
• Cell culture incubator (humidified, and supplied with CO2, depending on the 
requirements of the cell line). 
• Class II laminar flow hood for cell culture work. 
• Pipette aid with sterile pipettes (10 mL plugged pipettes with marked graduations 
recommended). 
• Centrifuge with swing-bucket rotor. 
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• Centrifuge tubes (15 mL and 50 mL conical recommended). 
• Cryo-vials/microcentrifuge tubes. 
• Pipette and pipette tips. 
• Cell counter (electronic or haematocytometer). 
• PPE for handling mice (as required by institutional regulations). 
• Heated rodent chamber.  
• Rodent restrainer. 
• 1 mL syringes and 27’ gauge needle. 
• Necropsy equipment (scissors and tweezers, exact type depends upon personal 
preference). 
• Optional: light microscope (if determining metastatic burden by H&E-stained paraffin 
sections) or method to homogenise tissues and qPCR instrument and analysis software 
(if determining metastatic burden by mCherry qPCR) 
 
 
PROCEDURE 
 
Passaging of cells to be injected  TIMING 30 min (2-3 d before animal injection) 
1. Use standard procedures recommended for the specific cell line in use and passage the 
cells such that on the day of the experiment the cells are ~80% confluent. Ideally, the 
cells should be passaged no sooner than 2-3 days prior to the experiment, to ensure 
they are in log-phase growth.  
 CRITICAL STEP The cells should be passaged at least once after being removed 
from liquid nitrogen before being used in the assay, but no more than five times. 
Prolonged culture in vitro or passaging can lead to reduced tumourigenicity in vivo. 
 
Preparation of cells to be injected  TIMING 30 min (day of injection) 
2. Harvest cells as required in a culture hood, and determine their concentration using a 
cell counter (either electronic or haematocytometer). 
3. Remove the appropriate amount of cell suspension required and centrifuge at 300 g for 
3 min at room temperature. 
 CRITICAL STEP You should always prepare approximately 20% extra cell suspension 
as some cells will be lost in the void volume of the needle and syringe. 
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4. Discard the supernatant and resuspend the pellet in the appropriate volume of PBS (100 
uL administered per mouse). Aliquot the cell suspension into cryo-vials/eppendorfs and 
place on wet-ice. Bring this to the animal house. 
 
Preparation of the recipient mice  TIMING 10 min (day of injection) 
5. In the animal room, turn on the hotbox and allow it to reach the desired temperature (38 ± 1°C). 
6. Place mice inside the hotbox (each cage can go into a compartment of the hotbox, no 
need to separate the mice from one cage into individual compartments of the hotbox). 
7. Have the rodent restrainer in position, as well as the required number of syringes and 
needles (depending on the number of mice to be dosed). 
 
Injection of the mice  TIMING 10-40 min, depending on the number of mice 
 CRITICAL STEP You should be as efficient as possible, as the cells will deteriorate 
sitting in the PBS for long periods and you want to avoid a significant difference in the 
number of metastases between mice dosed at the beginning of a dosing session and 
the end of the session. 
8. Mix the gently cells (by inverting the tube several times), fill the syringe and place the 
needle on the end. ! CAUTION Remove all air bubbles before placing the needle on the 
end of the syringe and then again be sure to push the plunger till the cell suspension 
comes out the end of the needle – air bubbles can lodge in the small capillaries of the 
mouse and cause immediate death. 
9. Immediately place a mouse from the hotbox into the restrainer and locate one of the two 
lateral tail veins (either by turning the tail 90° or rotating the whole restrainer 90°). 
10. Inject the tail vein with the desired volume (typically 100-200 uL) and then remove the 
mouse from the restrainer and house as before the injection.  
 CRITICAL STEP Ideally inject no more than ~5 mice per syringe to ensure that the 
cells are not sitting in the syringe for too long and have a chance to settle out of 
suspension. Use a fresh needle/syringe every ~5 mice to ensure the needle doesn’t 
become blunt (making it more painful for the mice) and no cells that have come out of 
suspension are mixed in with fresh cells suspension being drawn into the syringe. ! 
CAUTION Never draw up cells into the syringe with the needle attached as it may lyse 
them.  
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Determination of metastatic burden  TIMING 2 min to 2 days, depending on the number 
of mice and particular method used (3 methods listed below) 
 
11. Humanely sacrifice the mice as required by your local authority and remove the organ(s) 
of interest. Typically this will be the lung thus all steps hereafter only mention “lung”, 
however depending on the cell line used, this may also be the liver and/or other organs. 
12. Rinse the organ in PBS and dissect out all 5 lobes of the lung.  CRITICAL STEP Be 
sure to collect (and count) all 5 lobes, as a single lobe will not necessarily be 
representative of the metastatic burden of the entire organ (since metastatic burden is 
never equally distributed between the lobes). 
 
(i) macroscopic counting  TIMING 2 min per mouse, depending on the number 
metastatic colonies (10-30 days post-injection, depending on the cell line used) 
13. Either by eye or with the use of a dissecting microscope, count the number of metastatic 
colonies on the surface of all 5 lobes of the lung, on both sides of the lungs to obtain the 
total metastatic burden for that mouse. ! CAUTION Care needs to be taken if Bouin’s 
solution is used to fix and stain the lungs to aid visualization of the metastatic colonies 
as this reagent is toxic (thus needs to be done in a ventilated fume hood). 
 
(ii) H&E-stained paraffin sections  TIMING 2 days for processing of the tissues and 5 
min counting per mouse, depending on the number metastatic colonies 
14. Re-hydration, paraffin-embedding, sectioning and H&E-staining of the lungs can be 
performed by routine histopathology methods, and the number of metastatic colonies 
on the section of all 5 lobes of lung can be counted to obtain the total metastatic burden 
for that mouse. 
 
(iii) mCherry qPCR  TIMING 2 days for DNA extraction of the tissues and 1-2 hours for 
qPCR 
15.  Homogenise all 5 lobes of the lung in 1 mL TBSTx (1x Tris-buffered saline with 0.5% 
Triton X-100). 
16. Use 100 uL of the homogenate to extract genomic DNA (we use Puregene Core A, 
Qiagen) with the remainder of the homogenate being stored at -20°C for future use if 
desired. 
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17. Perform qPCR to determine the relative tumour burden – this can be achieved in a 
duplex reaction using a FAM-conjugated mCherry probe and VIC-conjugated Vimentin 
probe that is primer limited. 
18. The qPCR reaction is performed in triplicate per tissue sample loading 50 ng of genomic 
DNA or 1 ng genomic DNA from the tumour cell line (positive control) or water and 
undosed tissue (both negative controls). 
19. Setup the qPCR according to the manufacturer’s instructions (we use Quantinova probe 
PCR kit) and perform 50 cycles of amplification. 
20. Once complete determine the cycle threshold for each well for both the mCherry and 
vimentin probe. 
21. Derive the relative tumour burden using the following equation: 
•  Relative tumour burden = 100000 x 2-ΔCT 
• ΔCT = CT mCherry – CT vinculin (where there is no mCherry amplification, the 
CT value is set to 50 or the number of cycles used for amplification). 
 
TIMING 
Step 1, passaging of the cells to be injected: 30 min (2-3d before animal injection) 
Step 2, preparation of cells to be injected: 30 min (day of injection) 
Step 5, preparation of recipient mice for dosing: 10 min (day of injection) 
Step 8, injection of the mice: 10-40 min (depending on the number of mice to be dosed) 
Step 11, determination of metastatic burden: variable (depending on method used) 
 
 
? TROUBLE SHOOTING 
 
Trouble shooting advice can be found in Table 1. 
 
ANTICIPATED RESULTS 
The anticipated results with the experimental metastasis assay depend on several factors. The 
number (and tissue site) of metastatic colonies formed will be dependent upon the cell line 
used to dose the mice, the dose of cells used, and the mouse genetic background, sex, age 
and mutant status. For large-scale mouse phenotyping of metastatic colonisation using a dose 
of 4x105 mouse melanoma B16-F10 cells, wildtype C57BL/6 mice typically show 100 or 150 
pulmonary metastatic colonies at 10 days post-dosing when analysed by macroscopic counts 
(for males and females, respectively; values ≤ 35 counts indicate the entire dose was not 
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successfully administered into the vein). The successful procedure is dependent upon 
accuracy in locating and administering the full dosing volume to the tail vein, in a rapid and 
reliable manner. 
 
 
BOX 1: Sources of variation in the experimental metastasis assay 
Below we highlight factors that can significantly affect the metastatic colonisation rates 
and thus need to be considered in the experimental design.  
 
Sex 
We found that female mice had significantly higher rates of pulmonary metastatic 
colonisation (increased number of metastatic colonies on the lungs) compared to males 
(Figure 4a). Thus it is important to use sex-matched mice. 
 
Genetic background 
We found that the genetic background of the mouse can affect the number of pulmonary 
metastases (Figure 4b), which is most likely due to potential MHC (H2) haplotype differences 
between the strain of the mouse and the strain from which the tumour cell line was derived. 
For example, the B16-F10 mouse melanoma cell line is derived from a C57BL/6 mouse, and 
we find significant differences pulmonary metastatic colonisation of these cells between 
C57BL/6 and 129S5 mouse strains (which are both H2b) and the BALB/c and CBA mouse 
strains, which are H2d and H2k, respectively. Thus it is important to ensure that the control and 
mutant mice used in any experimental metastasis assay are strain-matched. 
 
Age 
We found that the age of the mouse can affect pulmonary metastatic colonisation ability, 
with younger mice having a higher tumour burden (Figure 4c). This may be a due to a relatively 
immature immune system and/or decreased blood volume in younger mice relative to older 
mice. Thus the age of the mouse is an important fact to consider and we recommend using 
mice at 6-8 weeks of age wherever possible. 
 
Assay date 
 By performing the experimental metastasis assay as part of a large-scale phenotyping 
pipeline, we found that similar to other phenotyping variables [Karp et al., 2012; 26], assay date 
is a major source of variation (Figure 4d). This variation arises from multiple sources, including 
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the researcher, culture and preparation of tumour cells and the cage. As this temporal variation 
has significant impact on data analysis, with counts done on the same day being more similar 
to themselves than counts done on another day, the solution is to compare mice assayed on 
different days using the ‘metastatic ratio’ (MR). The MR is calculated by dividing the counts for 
the experimental mice by the counts for the control mice dosed on the same day (this can be 
either mutant mice versus control mice  (Figure 3b) or mice dosed with modified cells versus 
control cells). 
 
Statistical power 
Using C57BL/6 wildtype data, we estimated that the average metastatic burden for mice 
dosed with 5x105 B16-F10 cells was 186 with standard deviation of 44 for males and 256 with 
a standard deviation of 87 for females (from a study comparing male and female animals, 
n=13/group). Where statistical power (or sensitivity) is the probability of making the correct 
decision when the biological effect actually exists, a power analysis for a two-tailed Mann-
Whitney test, using G*Power 3.1.9.2, assuming the underlying distribution is normal, found a 
60% change in mean (equivalent to the metastatic ratio filter we routinely use) had a statistical 
power of 0.921 and 0.724 for males and females, respectively, at 0.05 significance threshold. 
 
 
BOX 2: Methods to determine metastatic burden of a tissue 
Below we detail the different techniques that are available to determine the relative 
metastatic burden of a tissue after administration of tumour cells to the mouse.  
 
Macroscopic 
Macroscopic counting of the number of metastatic lesions by eye (or under a low-
powered/dissecting microscope) immediately after dissection has the advantage that it is quick, 
easy and no specialized skills or equipment are required. The disadvantage of this, however, 
is that it is only applicable to pigmented cell lines, such as melanomas. Alternatively, it is 
possible to fix organs in Bouin's solution for 24 hours, followed by 100% ethanol washes, which 
makes the tumour cells appear white, and thus able to be counted. 
 
Histopathology 
 Fixation of the relevant tissue, followed by embedding in paraffin, sectioning and 
haematoxylin and eosin (H&E) staining is a method that can be used to determine metastatic 
colonisation of any organ, by any tumour cell line administered. This technique has the 
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advantage that the tissue can be serially sectioned and thus the tumour burden of the whole 
tissue/organ can be determined. It can also allow for measurement of the individual metastatic 
lesions, thus can provide both quantitative and qualitative information about the metastatic 
colonisation phenotype of that mouse. It can also inform as to the presence of other cell types 
present in the organ, such as immune infiltrates. The disadvantage is that it depends on the 
researchers access to histology tools/services and/or a pathologist, and is not as quick as the 
macroscopic method. 
 
Quantitative polymerase chain reaction (qPCR) 
 The use of qPCR to determine metastatic colonisation of an organ can be achieved 
once the tumour cell line has been transfected with a marker, typically mCherry. In this case, 
the tissue can be collected for DNA extraction and qPCR performed to assess the level of 
mCherry (from the tumour cells) relative to the level of vimentin (from both the tumour cells and 
the tissue; an internal control). The advantage of this technique is that the total tumour burden 
of the tissue can be assessed, rather than only what appears on the surface of the tissue 
(macroscopic method) or on the particular section (histopathology method). The disadvantage 
of this technique is that it requires transfection/drug selection of the cell line, which may be 
difficult depending on its amenability to be transfected and may also alter the in vivo properties 
of the cell line. This method also requires access to a qPCR machine. 
 
 
FIGURE LEGENDS 
 
Figure 1. Schematic of the metastatic process and experimental procedures to model 
metastasis in the mouse. A healthy cell acquires the necessary mutations to become 
malignant and proliferates to form a primary tumour mass. (1) Metastasizing tumour cells 
invade the basement membrane, and (2) undergo intravasation into the circulation (or 
lymphatics). (3) The circulating tumour cells must then survive, arrest and (4) extravasate the 
circulatory system. (5) Survival after arriving at the secondary site is the rate-limiting step of 
the metastatic process, as the newly arrived tumour cell can undergo apoptosis, remain as a 
single cell or occult micrometastasis which can remain dormant for years, or (6) proliferate and 
progressively colonise the organ. There are 3 ways to models of metastasis in the mouse, 
involving the autochthonous model, the spontaneous metastasis assay or the experimental 
metastasis assay. The steps of the metastatic pathway that these techniques mimic is indicated 
by the arrows, with the boxes detailing the nature and timeframe of each of these procedures. 
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Figure 2. Schematic of the experimental metastasis assay using tail vein injection. The 
tumour cells are thawed and subsequently passaged before being harvested for tail vein 
injection into recipient mice. Ten days later, the tissue(s) can be collected (lungs are the 
predominant colonisation organ after tail vein administration) and examined for their metastatic 
tumour burden either by eye (if the cells are pigmented, such as the B16-F10 mouse melanoma 
cell line shown), by light microscopy examination of haematoxylin and eosin-stained paraffin-
embedded tissue sections (for all cell types, such as the MC-38 mouse colorectal 
adenocarcinoma cell line shown; x50 magnification) or by quantitative polymerase chain 
reaction (qPCR) of the tissue for mCherry expression levels relative to endogenous vimentin 
expression levels (for all cell types once transfected with an mCherry-expressing plasmid, such 
as the EO771.LMB mouse breast cancer cell line). 
 
Figure 3. Applications for the experimental metastasis assay. a, Female mice were tail 
vein dosed with 1x105 of either metastatic B16-F10 melanoma cells or highly metastatic B16-
BL6 melanoma cells and the number of pulmonary metastatic foci counts at day 10. b, Mutant 
mouse lines (assayed with sex-, age-, and background matched wildtype controls) were tail 
vein dosed with B16-F10 cells and 10 days later the number of pulmonary metastatic foci 
counted by eye, with the result represented as a ‘metastatic ratio’ (mean number of metastases 
for the mutant line divided by the mean number of metastases for concurrently assayed 
wildtype controls, thus allowing comparison of mutant lines tested on separate days). c, 
Examples of mutant mouse lines, with respective controls (+/+), that show an ability to regulate 
metastasis with homozygous Arhgef1 mutant (Arhgef1tm1a(EUCOMM)Wtsi) mice showing decreased 
metastatic colonisation and homozygous Slc9a3r2 mutant (Slc9a3r2tm2a(EUCOMM)Hmgu) mice 
showing increased metastatic colonisation. d, Bone marrow chimaeras (irradiated female 
wildtype mice transplanted with donor bone marrow) were tail vein dosed with 4x105 of B16-
F10 melanoma cells and 10 days later the number of metastatic foci counted by eye. The donor 
bone marrow came from either wildtype (+/+) or homozygous Arhgef1 mutant 
(Arhgef1tm1a(EUCOMM)Wtsi) mice. e, Wildtype female mice were in vivo depleted for natural killer 
(NK) cells by intra-peritoneal (i.p.) administration of ASGM1 antibody at -3 days, -1 hour and 
+5 days, with tail vein dosing of 4x105 of B16-F10 melanoma cells at day 0, and counting of 
the number of metastatic foci at day 10. Squares represent individual mice with error bars 
shown as SD, and statistical analysis performed using Mann-Whitney test (for a, c, d, e). Circles 
represent individual mutant mouse lines (b). Details on the cell lines and housing and 
husbandry of the mice used in these experiments are given in Supplementary File 1. 
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Figure 4. Effect of sex, genetic background and age on the experimental metastasis 
assay metastatic colonisation and variation of results of the assay over time. a, Male and 
female mice tail vein dosed with 5x105 B16-F10 cells. Squares represent individual mice with 
error bars shown as SD. Statistical analysis was performed using Mann-Whitney t test. b, 
female mice tail vein dosed with 5x105 B16-F10 cells, squares represent individual mice with 
error bars shown as SD. Statistical analysis was performed using a Kruskal-Wallis test with 
post hoc testing using a Dunn’s multiple comparisons test. c, Female mice of different ages 
were tail vein dosed with 4x105 B16-F10 cells. Squares represent individual mice with error 
bars shown as SD. Statistical analysis was performed using a Kruskal-Wallis test with post hoc 
testing of all groups against other using a Holm-Sidak’s multiple comparisons test (the P value 
shown is comparing the 3 week age with each of the other age groups). d, Graph showing the 
variation in the metastasis count over a 46-month period (within the dates shown) of wildtype 
mice on a B6N background, aged 7.5 to 9.4 weeks, administered 4x105 B16-F10 cells. Vertical 
ticks indicate individual assay dates, solid horizontal line indicates the mean and dashed 
horizontal line indicates the 95% confidence interval. The boxplot represents a five point 
summary of minimum, first quartile, mean, third quartile and maximum, which excludes outliers 
if they are >1.5 times the interquartile range (Q3-Q1) from the relevant quartile, and these are 
shown as circles on that day. Details on the cell lines and housing and husbandry of the mice 
used in these experiments are given in Supplementary File 1. 
 
Figure 5. Methods for determining metastatic burden of a tissue. a, Representative 
macroscopic image of lungs from three individual female mice, tail vein dosed with 4x105 B16-
F10 mouse melanoma cells (the black spots on the pink lobes of the lung are the metastatic 
colonies that can be counted by eye). b, Representative image of H&E-stained lungs from a 
male mouse, tail vein dosed with 1x106 LL/2 mouse lung carcinoma cells (x50 magnification; 
the box shows a large metastatic colony on a haematoxylin and eosin-stained, paraffin-
embedded section of mouse lung). c, Representative image of Bouin’s stained lungs from a 
male mouse, tail vein dosed with 1x106 mouse LL/2 lung carcinoma cells (the white spots on 
the yellow lobes of the lung are the metastatic colonies that can be counted by eye). d, 
Comparison of two methods of determining pulmonary metastatic colonisation (counting from 
H&E-stained paraffin sections versus counting by eye) on female and male wildtype mice 
dosed with 4x105 B16-F10 cells and the number of metastatic foci on the lungs of each mouse 
at day 10 first counted by eye, then put into formalin for histopathology processing (R2 value 
determined using a second order polynomial (quadratic) non-linear fit). e, Wildtype female mice 
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tail vein dosed with 4x105 of either B16-F10 mouse melanoma cells or F10CS cells (B16-F10 
cells stably-expressing mCherry) and pulmonary metastatic foci counted at day 10, show no 
difference in metastatic potential between the two cell lines (i.e., stable transfection of mCherry 
has not altered the metastatic properties of the cells). Squares represent individual mice with 
error bars shown as SD, and statistical analysis performed using a Mann-Whitney test. f, 
Wildtype female mice tail vein dosed with different numbers of F10CS cells and ‘metastatic 
burden’ determined at day 10 by qPCR on DNA extracted from the lungs (expression level of 
mCherry relative to endogenous vimentin expression), demonstrate the sensitivity of the assay. 
g, Comparison of two methods of determining pulmonary metastatic colonisation (qPCR versus 
counting by eye) on female wildtype and mutant mice dosed with 4x105 F10CS cells and the 
number of metastatic foci on the lungs of each mouse at day 10 first counted by eye, then DNA 
extracted from the lungs (R2 value determined using a second order polynomial (quadratic) 
non-linear fit). h, Female wildtype (+/+) and homozygous Arhgef1 mutant 
(Arhgef1tm1a(EUCOMM)Wtsi) mice tail vein dosed with 4x105 EO771.LMB cells and the lungs 
collected at day 10 for DNA extraction and qPCR (mCherry/vimentin). Squares represent 
individual mice with error bars shown as SEM, and statistical analysis performed using an 
unpaired two-tailed t test with Welch’s correction. Details on the cell lines and housing and 
husbandry of the mice used in these experiments are given in Supplementary File 1. 
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